Affiliation:
1. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
2. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD
3. Division of General Internal Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD
Abstract
OBJECTIVE
1,5-Anhydroglucitol (1,5-AG) is a biomarker of glucose peaks and has been associated with clinical cardiovascular disease. However, the association between 1,5-AG and subclinical cardiovascular disease is unknown. We investigated the association of 1,5-AG with subclinical myocardial damage (assessed by high-sensitivity cardiac troponin T [hs-cTnT]) and atherosclerosis (assessed by carotid intima-media thickness [CIMT] and carotid plaque).
RESEARCH DESIGN AND METHODS
We measured 1,5-AG, hs-cTnT, CIMT, and carotid plaque among 10,072 people without diabetes and 681 with diabetes who attended the second examination of the Atherosclerosis Risk in Communities (ARIC) Study (baseline, 1990–1992). We used Poisson regression to characterize the associations between 1,5-AG and prevalent elevated hs-cTnT, thick CIMT, or carotid plaque. Among 9,145 people with a second hs-cTnT measurement 6 years later, we used multinomial logistic regression to assess associations with incident elevation in hs-cTnT.
RESULTS
We found that in people with diabetes, lower 1,5-AG (<6 μg/mL) was cross-sectionally associated with elevated hs-cTnT (prevalence ratio 2.06, 95% CI 1.23–3.46) compared with higher 1,5-AG (≥10 μg/mL). Associations in people without diabetes and with thick CIMT or the presence of carotid plaque were less robust. Low 1,5-AG was prospectively associated with the 6-year incident elevation in hs-cTnT (relative risk 2.90, 95% CI 1.23–6.85) in people with diabetes. All associations were strongly attenuated with further adjustment for HbA1c.
CONCLUSIONS
In people with diabetes, 1,5-AG was associated with subclinical cardiovascular disease, particularly chronic subclinical myocardial damage. Nonetheless, whether observed associations are truly independent of average glycemia is unclear.
Funder
National Institute of Diabetes and Digestive and Kidney Diseases
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference39 articles.
1. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body;Yamanouchi;Am J Physiol,1992
2. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control;Yamanouchi;Diabetes Res Clin Pract,1994
3. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions;Dungan;Expert Rev Mol Diagn,2008
4. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control;Yamanouchi;Lancet,1996
5. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults;Selvin;N Engl J Med,2010
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献